Last reviewed · How we verify
Valsartan + Amlodipine besilate
Valsartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action.
Valsartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action. Used for Hypertension, Hypertension in patients with left ventricular hypertrophy.
At a glance
| Generic name | Valsartan + Amlodipine besilate |
|---|---|
| Also known as | Valsartan, Amlodipine besilate, VAL, AML |
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker + Calcium channel blocker combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, they provide complementary mechanisms for blood pressure reduction.
Approved indications
- Hypertension
- Hypertension in patients with left ventricular hypertrophy
Common side effects
- Dizziness
- Headache
- Peripheral edema
- Fatigue
- Hyperkalemia
- Cough
Key clinical trials
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Comparing Bisoprolol and Valsartan-Amlodipine for Hypertension (PHASE4)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity (PHASE4)
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension (PHASE3)
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan + Amlodipine besilate CI brief — competitive landscape report
- Valsartan + Amlodipine besilate updates RSS · CI watch RSS
- Novartis portfolio CI